Background: Over 180 single nucleotide polymorphisms (SNPs) associated with breast cancer
Introduction
Over 180 single nucleotide polymorphisms (SNPs) associated with breast cancer susceptibility have been discovered in genome-wide association studies (GWAS) [1] [2] [3] [4] . Though each SNP has a modest effect, multiple SNPs can be combined into a polygenic risk score (PRS) [5] . PRS has emerged as a promising tool for breast cancer risk stratification. The risk associated with having a PRS in the upper [20] [21] [22] [23] [24] [25] th percentile is similar to that of strong clinical risk factors such as having extremely dense breasts [6] , and adding PRS to risk models improves discrimination and reclassification [6] [7] [8] .
Ongoing clinical trials are studying the use of PRS to personalize breast cancer screening and prevention [9] . Some commercial genetic testing laboratories are already returning PRS results to those who tested negative for pathogenic moderate-or high-penetrance mutations [10, 11] .
A major barrier to the widespread use of PRS is the relative paucity of knowledge regarding its performance in non-European populations. To date, SNP discovery has overwhelmingly occurred in European populations [12] . However, the effect sizes, allele frequencies, and linkage disequilibrium patterns of SNPs vary by ancestry [12, 13] . Though relatively few studies have examined PRS performance in non-Europeans, they suggest that PRS constructed using European SNP summary statistics (effect size, allele frequency) typically perform worse in non-European populations [14, 15] .
Currently, commercial testing laboratories only provide breast cancer PRS results to women of European ancestry [10, 11] .
Disparities in the use and performance of PRS could especially affect Latinas. Latino/Latinas comprise the largest minority group in the U.S., representing 17.8% of the population in 2016 [16] . This diverse group includes genetically admixed individuals who have varying degrees of Indigenous American, European, African, and Asian ancestry [17] [18] [19] . We previously identified SNPs in the 6q25 locus associated with breast cancer risk exclusively in Latinas [20] . Most SNPs discovered in European populations display directional consistency in Latinas, with some also being nominally significant [20, 21] . One previous study assessed the performance of a breast cancer PRS in Latinas, finding that a 71-SNP PRS had worse prediction in Latinas as comparable PRS in Europeans [5, 15] . However, it included only 147 cases and did not account for genetic ancestry [15] .
We sought to test the performance of PRS in U.S. Latinas and Latin American women (collectively referred to hereafter as Latinas). To that end, we conducted a pooled case-control analysis of 8 studies comprising 13,631 Latinas. We examined the predictive performance of a 71-SNP and a 180-SNP PRS, and whether PRS performance varies by genetic ancestry.
Methods

Participants
Our analysis included 13,631 self-identified Latinas, of whom 5,697 women with invasive breast cancer were considered cases and 7,934 without breast cancer were controls. Participants came from 8 studies ( Tables 1 and S1 ). Recruitment details and patient characteristics have been previously reported for each study except for PGEN-BC. Studies are briefly described below and in more detail in the Supplement.
1) The San Francisco Bay Area Breast Cancer Study (SFBCS) plus the Northern California
Breast Cancer Family Registry (NC-BCFR), a population-based case-control study recruiting from the San Francisco Bay Area [22, 23] .
2) The Kaiser Permanente Research Project on Genes, Environment, and Health (RPGEH), a biobank recruiting from Northern California and the Pacific Northwest [24] .
3) The Multiethnic Cohort (MEC) study, a prospective cohort study recruiting from Southern California and Hawaii [25] .
4) The Cancer de Mama (CAMA) study, a population-based case-control study in Mexico [26] .
5) The Post-Columbian Study of Environmental and Heritable Causes of Breast Cancer (COLUMBUS-Colombia), a population-based case-control study in southern Colombia [20] .
6) The Post-Columbian Study of Environmental and Heritable Causes of Breast Cancer (COLUMBUS-Mexico), a population-based case-control study in Mexico [20] . The COLUMBUS substudies (Colombia and Mexico) were analyzed as separate datasets given differences in study populations and genotyping methods.
7)
The Peru Genetics and Genomics of Breast Cancer Study (PEGEN-BC), a case-series from a Peruvian cancer center. Unrelated Peruvian individuals from 1000 Genomes [27] were used as controls.
8) The City of Hope Clinical Cancer Genetics Community Research Network (COH/CCGCRN), the Southern California site of a multisite cancer center and communitybased registry for familial breast cancer [28] .
All studies obtained local institutional review board approval and written informed consent from participants.
Genotyping and genetic ancestry
For all studies except COH/CCGCRN, genotyping was performed using high-density arrays (Table S1 ). Genotyping of COH/CCGCRN samples was performed using next-generation sequencing with a targeted capture kit that included all 89 SNPs identified as of 2016, prior to publication of the OncoArray GWAS results [3] . Further information about genotyping is provided in the Supplementary
Methods.
We estimated genetic ancestry from genome-wide markers using the program ADMIXTURE [29] Indigenous Americans previously genotyped on the Affymetrix Axiom LAT1 array [31, 32] . Women with >75% East Asian ancestry were excluded given that the limited influence of the East Asian component in the Hispanic/Latino population did not allow for a subgroup analysis.
Polygenic risk score
We used a 180-SNP PRS for our primary analysis (Table S2) . SNP selection is discussed in further detail in the Supplementary Methods. We performed sensitivity analyses of different imputation r 2 cutoffs for inclusion of SNPs in our PRS ( Table S3) . We ultimately included all SNPs regardless of imputation quality, as we did not find substantive differences in the associations between the 180-SNP PRS and a 168-SNP PRS constructed using an imputation r 2 threshold of > 0.5.
Since targeted genotyping was performed within COH/CCGCRN samples, genotypes were available for 89 SNPs. We dropped 1 SNP due to missingness. Of the remaining 88 SNPs, 63
overlapped and 8 had LD proxies (r 2 > 0.7) with the 180 SNPs comprising the main PRS. We used these 71 SNPs to construct a PRS within the COH/CCGCRN dataset. We then constructed a comparator 71-SNP PRS in the 7 remaining datasets using the 63 shared SNPs and 8 respective LD proxies, and pooled all 8 datasets to evaluate the performance of the 71-SNP PRS.
We constructed the PRS as previously described [7, 33] . Briefly, the PRS represents the product of the likelihood ratios across multiple SNPs, assuming each SNP exerts an independent effect. The likelihood ratio for each SNP was calculated based on the number of risk alleles present, and the allele frequency and effect size (odds ratio, OR) of the risk allele. We used risk allele frequencies derived from the Latin American (AMR) population in 1000 Genomes [27] and published
ORs [3] . The latter predominantly reflects the effect of the SNP within a European population, except for those discovered in Latina studies (Table S2 ) [20, 21] .
Statistical analysis
First, we tested the associations between individual SNPs and breast cancer risk using multivariable logistic regression models adjusted for genetic ancestry and study. We used METAL [34] to perform inverse variance based meta-analysis of 180 SNPs across 3 studies: COLUMBUSColombia, COLUMBUS-Mexico, and pooled SFBCS/NC-BCFR, Kaiser RPGEH, MEC, CAMA, and PEGEN-BC studies.
To test the associations of PRS with breast cancer, we adjusted for genetic ancestry and study,
given that both remained independently associated with breast cancer risk when included in the same model as the PRS. We first performed linear regression of study and ancestry on the PRS (dependent variable). We then used the residual as the main predictor in univariate logistic regression with breast cancer as the outcome. We analyzed the residual as a continuous variable normalized to the mean and standard deviation (SD) in controls. We tested the discrimination of the adjusted PRS by estimating the area under the receiver operating characteristic curve (AUROC). We also tested calibration using the Hosmer-Lemeshow test across deciles of the adjusted PRS, with the 40-50 th and 50-60 th deciles combined and used as the reference group.
To examine the ancestry-specific performance of the PRS, we divided the pooled dataset into quartiles of IA ancestry. We performed logistic regression within each quartile of IA ancestry and compared the resulting coefficients using a Wald test of linear hypothesis. To compare AUROC estimates, we performed a test of equality of AUROC as described by DeLong [35] . Given differences in the population structures between U.S. Latina and Latin-American studies, we also examined ancestry-specific performance of the PRS by geographic origin of study, specifically U.S. (SFBCS/NC-BCFR, RPGEH, MEC) versus Latin-American (CAMA, COLUMBUS, PEGEN-BC).
All tests for significance used two-sided a = 0.05. We developed the script to calculate the PRS using R (The R Foundation). We performed all statistical analyses using Stata 14.1 (StataCorp, College Station, TX).
Results
Study characteristics
Our pooled data included 13,631 women from 8 studies, for a total of 5,697 cases and 7,934 controls ( Table 1) . Across all studies, ancestry was mostly European and Indigenous American (IA).
There was substantial variation in ancestry within and across studies (Supplementary Figure S2) . For instance, PEGEN-BC in Peru had the highest average IA ancestry (76% in cases and controls) while RPGEH in Northern California had the lowest (27% in cases, 29% in controls). Within each study, cases tended to have similar or lower IA ancestry than controls, as we have previously reported [36, 37] . In the pooled analysis, cases had higher IA ancestry since nearly half the controls came from RPGEH, the study with the lowest IA ancestry.
Association of PRS with breast cancer risk
We first examined the associations between individual SNPs and breast cancer risk. Of 180
SNPs tested, 140 had associations that were directionally consistent with those reported in European populations (Table S2 ) [3] . Forty-eight SNPs were nominally significant (p < 0.05) in our dataset, with 43 being also directionally consistent. Six SNPs remained significant to p < 2.8´10 -4 after Bonferroni correction for multiple testing. Thirteen SNPs displayed heterogeneous associations across studies (Phet < 0.05). For both PRSs, the mean unadjusted PRS was higher in cases than controls (Table 1, Figure S1 ).
Our main analysis evaluated the performance of a 180-SNP PRS in 12,287 women (4,658 cases and 7,629 controls) from 7 studies, excluding COH/CCGCRN given that 89 SNPs were genotyped in that study. After normalization and adjustment for genetic ancestry and study, the 180-SNP PRS was strongly associated with breast cancer risk, OR per SD increment = 1.58 (95% CI 1.52 to 1.64) ( Table 2 
Performance of PRS by Indigenous American ancestry
The 180-SNP PRS displayed similar performance regardless of IA ancestry, with comparable
ORs and AUROCs across the top (>55%) and bottom (<29%) quartiles of IA ancestry ( Table 3 A major strength of our study was the size and diversity of our study population. Additionally, we accounted for genetic ancestry, which can bias associations in genetic studies [39] . Given that ancestry was a confounder and an independent predictor of breast cancer risk, we used a novel approach to calculate an "ancestry-adjusted" PRS. We also examined PRS performance by IA ancestry, which has not been previously done. Another strength was the inclusion of several large, diverse breast cancer studies representing populations from several geographic areas (Western U.S.,
Central and South America) and including women with varying degrees of IA versus European ancestry.
Our results should be interpreted in light of three limitations. First, the generalizability of our findings is limited to Latina populations with similar distributions of genetic ancestry, although the ancestry composition of our study resembled that of other large studies of Latinas from the western U.S. and Central/South America [19, 40] . However, our results may not be generalizable to Caribbean
Latinas, whose population structures have a higher proportion of African ancestry [17] [18] [19] . We did not test the performance of PRS according to African ancestry given that our study population predominantly consisted of women originating from Latin American countries, where African ancestry is limited. Secondly, our analysis included women recruited from community-based and familial breast cancer clinics and may include moderate or high-penetrance mutation carriers. While PRS is associated with breast cancer risk in mutation carriers and women with elevated familial risk, the magnitudes of these associations vary slightly from those in the average-risk population [41] . Finally, we tested a PRS containing 180 SNPs representing all known GWAS hits at the time of analysis.
However, others have constructed expanded PRSs comprising 313 and 3820 SNPs by including SNPs that did not have genome-wide significant associations with breast cancer [38] . Though these expanded PRSs performed better than a 77-SNP PRS, there was little difference in performance between the 313-SNP and 3820-SNP PRSs [38] . We included only SNPs with genome-wide significant associations in our PRS since we reasoned that these signals may be more robust across ancestry.
The AUROC for our 180-SNP PRS (0.63) was similar to that of the 313-SNP PRS [38] .
Our results suggest that the PRS has predictive value in Latinas, a large and rapidly-growing population in the U.S. Although studies on the ability of the PRS to inform decisions around screening and prevention are underway [9] , several commercial genetic testing laboratories are already returning PRS results to women of European descent who tested negative for deleterious mutations. If this practice were extended to Latinas, one could expect the PRS to perform comparably well. Even if the performance of the PRS were slightly attenuated in Latinas of higher Indigenous American ancestry, this does not necessarily preclude its use in this population. Instead, results could account for this attenuation and model the joint effects of PRS and ancestry.
Though our findings lend optimism to the utility of the PRS in predicting breast cancer risk among Latinas, they do not nullify the prospect of disparities in genetic discovery research [42] .
Whereas we studied mostly common variants, rare variants display more geographic clustering [43] .
As genetic association studies identify more rare variants, those discovered in European populations will be less generalizable to other populations.
Thus, high-quality genetic studies in non-European populations should remain a priority. Finemapping in large datasets may enhance the identification of causal SNPs associated with breast cancer risk. Likewise, GWAS should be intentional about including Latinas, particularly those with higher IA and/or African ancestry. In addition, future studies should prospectively assess prediction and examine the contribution of PRS to clinical risk models. Though one such trial is currently using the PRS to tailor decision-making around breast cancer screening and prevention [9] , similar clinical effectiveness studies should also aim to recruit diverse women. 
